NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Xencor, Inc. (XNCR) Stock Analysis

Xencor, Inc. (XNCR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

XNCR

$26.61

−$0.01 (−0.04%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XNCR with… →

XNCR Key Statistics

As of Sep 4, 2026
Trading
Open
$26.05
Previous Close
$26.62
Day's Range
25.40–26.76
52-Week Range
8.19–30.61
Volume
919.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$1.98B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.85
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.16
Financials (FY)
Revenue (FY)
$125.58M+13.65%
Net Income (FY)
−$91.92M
Profit marginThe share of revenue left as profit after all costs and taxes.
−155.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
74.35M
1-Year Return
+217.92%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
1.15M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XNCR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+73.81%
2025−33.38%
2024+8.24%
2023−18.47%
2022−35.09%
2021−8.04%
2020+26.87%
2019−4.89%
2018+64.96%
2017−16.72%
2016 (partial year)+22.48%

As of September 4, 2026.

XNCR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$125.58M−$91.92M−73.2%
2024$110.49M−$232.62M−210.5%
2023$174.62M−$133.13M−76.2%
2022$164.58M−$55.18M−33.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$125.58M—−$177.50M−$91.92M−73.2%
2024$110.49M—−$178.41M−$232.62M−210.5%
2023$174.62M—−$132.36M−$133.13M−76.2%
2022$164.58M—−$82.47M−$55.18M−33.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XNCR Valuation vs Biotechnology Median

Median of 656 stocks
MetricXNCRBiotechnology medianvs median
P/S ratio18.8515.2623% above
Profit margin−155.59%0.00%155.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Xencor, Inc. (XNCR) at $1.98B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 260.

The 52-week range on file runs from $8.19 to $30.61. The most recent close on file for XNCR is $26.61, dated September 4, 2026. That is −$0.01 (−0.04%) against the previous close. The latest close sits 224.91% above that 52-week low.

Financial Health

In fiscal 2025, Xencor, Inc. reported revenue of $125.58M. That is +13.65% against the prior fiscal year, when revenue was $110.49M. The same year closed with a net loss of $91.92M. Profit margin runs at −155.59%. That is 155.6 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −2.16.

Across the 4 fiscal years on file, revenue moves from $164.58M in 2022 to $125.58M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 18.85. On price-to-sales that is 23.48% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.88. Daily returns over the trailing 10 years annualize to a volatility of 54.12%. Over the trailing twelve months the price has returned +217.92%. Measured over 10 years, that is +2.72% a year compounded.

Growth & Income

The record shows no dividend for XNCR.

So far in 2026 the price is +73.81%. The strongest complete calendar year on file is 2018 at +64.96%; the weakest is 2022 at −35.09%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Xencor, Inc. (XNCR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xencor, Inc. XNCR $1.98B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Xencor, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Xencor, Inc.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Visit website →